Form 4: Pliant Therapeutics Director Granted 30,000 Stock Options

Pliant Therapeutics, Inc. Director Suzanne Louise Bruhn was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year.

Summary

• Suzanne Louise Bruhn, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 derivative securities in the form of a right to buy Common Stock.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these options is $1.61 per share.
• The options have an expiration date of June 5, 2035.
• The vesting schedule for these options is as follows: 25% on October 1, 2025; 25% on January 1, 2026; 25% on April 1, 2026; and the remaining 25% on the earlier of the one-year anniversary of the June 5, 2025 grant date or the next annual meeting of stockholders.
• Vesting is contingent upon Ms. Bruhn's continued service as a Director.
• Following this transaction, Ms. Bruhn beneficially owns 30,000 derivative securities directly.
• A Limited Power of Attorney was executed on June 5, 2025, by Suzanne Bruhn, appointing specific individuals to execute SEC filings on her behalf.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is a positive for corporate governance and alignment of interests. There are no negative financial implications or operational setbacks reported. The Power of Attorney is a routine administrative document.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term performance and value creation.
• The exercise price of $1.61 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• No direct negatives are apparent from a standard Form 4 filing, which primarily reports insider transactions.

Risks

• The Power of Attorney document includes an indemnification clause where the undersigned (Suzanne Bruhn) agrees to indemnify the attorneys-in-fact and the Company from any demand, damage, loss, cost, or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact, highlighting the importance of accurate disclosure.

Future Outlook

The stock option grant includes a specific vesting schedule extending into 2026, indicating a future commitment and incentive for the director's continued service and contribution to the company's performance. The options expire in 2035, providing a long-term incentive horizon.

Management Comments

• The filing was signed by Jennifer Woo, attorney-in-fact, on behalf of Suzanne Bruhn.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director. Such grants are common practice in the biotechnology and pharmaceutical industries, like Pliant Therapeutics, to attract and retain experienced board members and align their interests with long-term company success. It does not provide broad industry trends but reflects standard corporate compensation practices.

Comparison to Industry Standards

• Granting stock options to directors is a common compensation practice across publicly traded companies, particularly in the biotech sector, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule, typically over 1-4 years, is standard for director equity grants, ensuring continued service. For example, similar vesting schedules are observed at companies like Gilead Sciences or Amgen for their non-employee directors, often tied to annual board service or specific performance milestones.
• The exercise price being set at a specific value ($1.61) is typical for options, reflecting the stock price at or near the grant date, which is a standard practice to ensure the options have intrinsic value only if the stock price appreciates.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Suzanne Louise Bruhn, a Director of Pliant Therapeutics, Inc., constitutes a transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options become valuable only if the stock price increases above the exercise price.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The Power of Attorney facilitates compliance for the director, reducing administrative burden on management for SEC filings.

Next Steps

• The granted stock options will vest according to the specified schedule: 25% on October 1, 2025, 25% on January 1, 2026, 25% on April 1, 2026, and the final 25% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders.
• Suzanne Bruhn will continue her service as a Director of Pliant Therapeutics, Inc. to fulfill vesting conditions.

Key Dates

Recommendation

Keywords

Pliant Therapeutics, PLRX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule, Corporate Governance